White House pushes drug pricing reform amid GSK inhaler price disputes

The White House is advancing a 'most-favored nation' drug pricing bill to benchmark U.S. costs against other countries, despite Republican opposition labeling it government overreach. Concurrently, GSK replaced a widely used asthma inhaler with a higher-priced authorized generic, sparking access and affordability issues highlighted by Senator Maggie Hassan. These developments underscore ongoing tensions around drug affordability and market practices, signaling continued legislative battles and scrutiny of pharmaceutical pricing strategies ahead.